PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$15.79M
Enterprise ValueC$15.68M
Total Cash (Recent Filing)C$564.71K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported total debt provides structural financial flexibility for a clinical-stage biotech. Without leverage the company has lower fixed financing costs and greater optionality to fund operations, partnerships, or scale manufacturing through equity or non-debt arrangements over the next 2-6 months.
Specialized GMP MDMA Supply FocusA clear, narrow business model—producing pharmaceutical-grade MDMA for regulated clinical trials and potential prescriptions—creates durable competitive positioning. GMP supply for controlled substances involves high regulatory barriers, recurring demand from trials, and specialized capabilities that limit easy new entrants.
Positive Revenue Growth TrendTrailing-twelve-month revenue growth indicates market traction for the company's products/services. Sustained top-line growth provides a foundation to achieve scale, improve gross margins, and leverage fixed-cost investments if management can arrest margin declines and convert demand into profitable scale.
Bears Say
Negative Gross Profit And Operating LossesNegative gross profit signals that unit economics are currently unsustainable: production or direct costs exceed revenue before operating expenses. Persistent operating losses erode retained capital and complicate long-term commercialization unless per-unit costs or pricing materially improve.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow forces reliance on external financing to fund R&D and GMP manufacturing. This creates dilution and execution risk, constrains strategic investments, and limits the company's ability to self-fund trials or commercial rollouts until cash generation reverses.
Deteriorating Unit Economics Vs Prior YearA reversal from prior positive gross profit to current negative margins indicates unstable unit economics or scaling inefficiencies. This trend raises structural execution risk: recurring profitability gains are not yet assured and could impair ability to convert trial supply momentum into sustainable commercial margins.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$15.79M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Jul 24, 2026 which is in 66 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on May 04, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---